Molecular pathology of breast cancer and its impact on clinical practice

Schweizerische Medizinische Wochenschrift

Volumn 129, Issue 46, 1999, Pages 1749-1757

  Steel, C M ^a   Smyth, E ^b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Familial; Genes

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CONFERENCE PAPER; FAMILIAL CANCER;

BREAST NEOPLASMS; FAMILY; FEMALE; HUMANS; MOLECULAR BIOLOGY; PEDIGREE;

EID: 0033589775     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Haber DA, Fearon ER. The promise of cancer genetics. Lancet 1998;351:SII,1-8.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorgenesis. Cell 1990;61:759-67.
3. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
4. Kolodner RD. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 1995;20: 397-401.
5. Kinzler KW, Vogelstein B. Cancer susceptibility genes. Gate-keepers and caretakers. Nature 1997;386:761-3.
6. Samowitz WS, Salttery ML, Kerber RA. Microsatellitc instability is not a useful clinical indicator of familial colorectal cancer. Gastroenterol 1995;109:1765-71.
7. Tomlinson I, Bodmer WF. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nature Med 1999;5:11-2.
8. Rustgi AK. Cyclo-oxygenase-2: the future is now. Nature Med 1998;4:773-4.
9. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Traet 1994;32:5-12.
10. Devillee P, Cornelisse C. Somatic changes in human breast cancer. Biochim Biophys Acta 1994;1198:113-30.
11. Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chrom Cancer 1995;14:227-51.
12. Steel CM. Cancer of the breast and female reproductive tract. In: Emery AEH, Rimoin DL, editors. Principles and Practice of Medical genetics. 3rd ed. New York: Churchill Livingstone; 1996. p. 1501-23.
13. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 1993;66:83-92.
14. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. p53 mutations in breast cancer. Cancer Res 1992;52: 5291-8.
15. Varley JM, Evans DGR, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer 1997;76:1-14.
16. Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji HL, Dann J. Inherited mutations in PTEN that are associated with breast cancer, Cowden disease and juvenile polyposis. Am J Hum Genet 1997;61:1254-60.
17. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S. A strong candidate for the breast-ovarian cancer susceptibility gene BRCA1. Science 1994;266: 66-71.
18. Wooster R, Bignell G, Lancaster J, Swift S; Seal S, Mangion J. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
19. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-38.
20. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 1996;5: 1515-9.
21. Szabo C, King M-C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013-20.
22. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germline mutations. Cancer Res 1997;57:1222-7.
23. Crook T, Crossland S, Crompton M, Osin P, Gusterson BA. Molecular changes in BRCA-associated breast cancer. Lancet 1997;350:638-9.
24. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
25. Lakhani SR, Jacquemeier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
26. Lakhani SR, Gusterson BA, Jacquemeier J, Sloane JP, Anderson TJ, van de Vijver MJ. The pathology of familial breast cancer: histological features of cancers in families not due to mutations in BRCA1 or BRCA2.
27. Paterson JWK. BRCA1: a review of structure and putative functions. Dis Markers 1998;13:261-74.
28. Gayther SA, Ponder BAJ. Clues to the function of the tumour susceptibility gene BRCA2. Dis Markers 1998;14:1-8.
29. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A 1998;95:13869-74.
30. Cull A, Anderson EDC, Campbell S, Mackay J, Smyth E, Steel M. The impact of genetic counselling about breast cancer risk on women's risk perceptions and levels of distress. Br J Cancer 1999;79:501-8.
31. Evans DGR, Blair V, Greenhalgh R, Hopwood P, Howell A. The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer 1994;70:934-8.
32. Lloyd S, Watson M, Waites B, Meyer L, Eeeles R, Ebbs S, et al. Familial breast cancer: a controlled study of risk perception, psychological morbididty and health beliefs in women attending for genetic counselling. Br J Cancer 1996;74: 482-7.
33. Ford D, Easton DF, Stratton MR, Narod SA, Goldgar D, Devilee P. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
34. Struewing JP, Hartge P, Wacholder S, Baker SM, Bertin M, McAdams M. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336: 1401-8.
35. Evans DGR, Kerr B, Foulkes W, Cade D, Hadfield L, Hopwood P, et al. False breast cancer family history in the cancer family clinic - a report of 8 families. Eur J Surg Oncol 1998;24:275-9.
36. Morrison PJ. Personal communication.
37. Collyer S, DeMey R. Public records and recognition of genetic disease in Scotland. Clin Genet 1987;31:125-31.
38. Vasen HFA, Haites NK, Evans DGR, Steel CM, Moller P, Hodgson S. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. Eur J Cancer 1998;34:1922-6.
39. Steel CM. Implications of studies of inherited predisposition for prevention and treatment. In: Ponder BAJ, Waring MJ, editors. Cancer Biology and Medicine. London: Kluwer Scientific; 1995. p. 159-76.
40. Moller P, Evans DGR, Anderson EDC, Maehle L, Lalloo F, Heimdal K. Disease Markers. In Press 1999.
41. Moller P, Machle L, Heimdal K, Dorum A, Apold J, Engelbretsen LF. Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer. Breast 1998;7:55-9.
42. Lalloo F, Boggis CRM, Evans DGR, Shenton A,Threlfall AG, Howell A. Screening by mammography, women with a family history of breast cancer. Eur J Cancer 1998;34:937-40.
43. Hartmann L, Jenkins R, Schaid D, Woods JE, Crotty TP, Myers JL. Prophylactic mastectomy: a retrospective cohort analysis. N Engl J Med 1999;340:77-84.
44. Fisher B, Costatnino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
45. Powles T, Eeles R, Ashley S, Easten D, Chang J, Dowsett M. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen chemoprevention trial. Lancet 1998;352:98-101.
46. Veronesi U, Maissoneuve P, Costa A, Sacchini V, Maltoni C, Robertson C. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
47. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Gene 1997;60:496-504.
48. Friend S. Breast cancer susceptibility testing: realities in the post-genomic era. Nature Genet 1996;13:16-7.
49. Steel CM, Smyth E, Vasen H, Eccles D, Evans G, Moller P. Ethical, social and economic issues in familial breast cancer: a compilation of views from the E,C. Biomed II demonstration project. Dis Markers; 1999. In Press.
50. Royal College of Physicians of London. Report "Ethical issues in clinical genetics". 1991.
51. Pembrey M, Anionwu E. Ethical aspects of genetic screening and diagnosis. In: Emery AEH, Rimoin DL, editors. Principles and Practice of Medical Genetics. 3rd ed. New York: Churchill Livingstone; 1996. p. 641-53.
52. Vandenbroucke JP. Maintaining privacy and the health of the public. Br Med J 1998;316:1331-2.
53. Hunt A. The patient's viewpoint. Dis Markers 1992;10: 205-10.
54. Human Genetics Advisory Commission. The implications of genetic testing for insurance. London; 1997, December.
55. American Society of Human Genetics, social issues subcommittee on familial disclosure. ASHG statement: Professional disclosure of familial genetic information. Am J Hum Genet 1998;62:474-83.
56. Harris J. The use of information (autonomy and confidentiality). Dis Markers 1992;10:195-8.
57. Nuffield Council on Bioethics. Genetic screening: ethical issues. London; 1993.
58. Rothenberg KH. Breast cancer; the genetic "quick fix" and the Jewish community. Health Matrix 1997;7:97-124.
59. Laurie GT. Negligence in genetic counselling and obligations to third parties. Acad Europ Law, Conference on the Law and Genetics. Edinburgh; 1999.
60. MacKay RD. Dangerous patients. Third party safety and psychiatrists duties - walking the Tarasoff tightrope. Med Sci Law 1990;30:52-60.